SIT PHARMA is pleased to announce the acquisition of OSTIDIL-D3 and KEFORAL
- OSTIDIL-D3 is indicated for the treatment of:
- Osteodystrophy due to renal insufficiency requiring or not dialysis;
- Hypoparathyroidism;
- Rickets and vitamin D resistant or dependent (pseudo deficit) osteomalacia;
- Rickets and osteomalacia from renal conditions due to vitamin D metabolism;
- Post-menopausal osteoporosis.
- KEFORAL is indicated for the management of:
- Respiratory tract infections caused by St.pneumoniae and beta-haemolytic Streptococcus (group A);
- Otitis media caused by St. pneumoniae, H. influenzae, staphylococci, streptococci and M. catarrhalis;
- Osteoarticular infections caused by staphylococci and/or P. mirabilis;
- Skin or soft tissue infections caused by staphylococcus and/or streptococci;
- Urinary tract infections, including acute prostatitis, caused by Escherichia Coli, Pr. Mirabilis, and Klebsiella sp;
- Dental infections due to staphylococci and streptococci;
- Bacterial sinusitis due to streptococcus, pneumococcus (D. pneumoniae) and St. aureus (only methicillin-sensitive).
Silvia Lunati, SIT Pharma’s General Manager, comments: “The acquisition of OSTIDIL-D3 and KEFORAL confirms our desire to enrich our Italian portfolio and to guarantee physicians and patients the best solutions for the treatment and prevention of widespread pathologies, in clinical areas not yet covered by us”.
SIT Pharma is an Italian-based pharmaceutical group with presence in over 70 countries which develops, produces and commercializes more than 80 branded pharmaceutical products, Medical Devices and Food supplements
About SIT PHARMA
SIT Pharma is a family-owned international pharmaceutical company, based in Italy since 1927, and today is an international pharmaceutical group with almost 100 years of experience and a recent history of prestigious acquisitions and global expansion. SIT Pharma is a reliable preferred acquirer for pharma businesses choosing to divest their “mature,” “established” or “tail” off-patent branded medicines.
In its two Italian manufacturing plants, SIT Pharma continues the high-quality “Made in Italy” drug manufacturing and management, aspiring to breathe new life into medicines, investing in them to renew the lifecycle and give new stability and sustainability over the long-term.
For more information, please visit our website www.sitpharma.com
